FY2025 · ended Dec 31, 2025 · Revenue $2.85M, +20.4% YoY · Filed Mar 26, 2026
Upstream Bio, Inc. (UPB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.9 million and a net loss of $143.4 million. Free cash flow was -$133.4 million. As of Jun 30, 2026 it held $261.3 million in cash and investments and $954,000 in total debt.
Revenue (TTM)
$3.16M
Net income (TTM)
$-156.50M
Operating cash flow (TTM)
$-136.34M
Free cash flow (TTM)
$-136.46M
EPS (TTM)
$-2.89
Dividend per share
None
Shares outstanding
54.42M
+1.5% vs prior year
Net cash
$260.35M
as of Jun 30, 2026
Operating margin
-5382.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022626
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $2.9M | $2.4M |
| Operating income | -$160.4M | -$77.8M |
| Net income | -$143.4M | -$62.8M |
| Diluted EPS | -$2.66 | -$5.58 |
| Operating cash flow | -$133.3M | -$59.2M |
| Free cash flow | -$133.4M | -$59.7M |
| Total assets | $353.8M | $481.7M |
| Total liabilities | $14.0M | $11.9M |
| Stockholders' equity | $339.8M | $469.9M |
| Cash and investments | $341.5M | $470.5M |
| Total debt | $1.3M | $1.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 134 Upstream Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.